Pfizer links up with heart disease AI developer Anumana to build cardiac amyloidosis diagnostics

Related Articles
Bridging ECG Signals and EHR data through Contrastive Learning
Introduction: How can we teach an AI to see the connections between a patient’s heart rhythms and their clinical notes? In healthcare, critical information is spread across different data types…January 22, 2026
Mayo Clinic Launches Two Companies To Improve AI Diagnostic And Preventative Care
Healthcare Technology Report: Artificial Intelligence (AI) continues to improve the healthcare industry. Capitalizing on AI’s many applications, Mayo Clinic is currently launching two new ventures, Anumana and Lucem Health, in…April 28, 2021
Anumana’s Pfizer-backed cardiac amyloidosis-spotting AI algorithm nabs FDA breakthrough tag
Fierce Biotech: For the fourth time in half as many years, Anumana has earned the FDA’s breakthrough device designation for another of its artificial intelligence algorithms designed to catch hard-to-spot…June 22, 2023
Anumana Appoints Harry S. Palmin as CFO
Anumana Appoints Harry S. Palmin as CFOCAMBRIDGE, Mass. – May 14, 2024 Anumana, a leading AI-driven health technology company and portfolio company of nference, today announced the appointment of Harry…May 14, 2024


